Table 1.

Characteristics of all patients (n = 21)

Variables	All lesions (n = 21) (range)
Treatment duration, days (median)	111 (range 15–443)
Age, years (median)	71 (range 50–84)
Gender
Male/female	18/3
Etiology
HBV/HCV/alcohol/NASH	2/12/4/3
Child–Pugh classification
A/B	16/5
Previous treatment y/n	19 (TACE/RFA:17/14)/2
Post-treatment, TAI or TACE/HAIC/none	4/8/9
BCLC, B/C	12/9
Vascular invasion, y/n	4/17
Extrahepatic metastasis, y/n	5/16
AFP, ng/mL (median)	11.7 (range 1.7–34.8)
DCP, mAU/mL (median)	149 (range 17–60,347)
NLR	2.1 (1.2–6.3)

HBV hepatitis B virus, HCV hepatitis C virus, NASH non-alcoholic steatohepatitis, RFA radiofrequency ablation, TACE transarterial chemoembolization, TAI transarterial infusion, HAIC persistent hepatic transarterial infusion chemotherapy, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, DCP des-γ-carboxy prothrombin, NLR neutrophil to lymphocyte ratio